AzTrials
AzTrials

Confinement and IsolationICELAND-2NCT03746145

A Counter Measure for the Effects of Immune and Microbiome Changes in Environments With Limited ANtigen Diversity (ICELAND-TWO)

A study testing Bifidobacterium longum 1714 in people with Confinement and Isolation, run by University Hospital Tuebingen at 1 site in Antarctica.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

There is evidence to indicate that the gut microbiota has an effect on mental well-being and stress behaviours. This is highly relevant to both life on earth and spaceflight missions, in which mental well-being is crucial to mission success. Read more about this study

Who is it for?
Ages 18 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Confinement and Isolation
What is being tested?
Bifidobacterium longum 1714
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteAntarctica
Study dates
15 Nov 2018to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Crew members of the Concordia station in Antarctica

Who cannot join

  • Participants which are not crew members of the Concordia station in Antarctica

Trial locations and contacts

1 site in 1 country.

Paul Enck, Prof. contact

paul.enck@uni-tuebingen.de

Antarctica1 site, 1 recruiting
  • Concordia Station

    Concordia Station

    Isabelle Mack, Dr., isabelle.mack@uni-tuebingen.de

    Recruiting

About this study

Official title: A Counter Measure for the Effects of Immune and Microbiome Changes in Environments With Limited ANtigen Diversity (ICELAND-TWO) - a Randomized Double Blind Controlled Pilot Study With Bifidobacterium Longum 1714

There is evidence to indicate that the gut microbiota has an effect on mental well-being and stress behaviours. This is highly relevant to both life on earth and spaceflight missions, in which mental well-being is crucial to mission success. Bifidobacterium longum 1714 (BL 1714), will be tested in the project ICELAND-2 in a double-blind, randomized placebo-controlled pilot study in crew members of the Antarctica station CONCORDIA in order to test stress resilience and possible outcomes on the immune system since the metabolic stress response and the immune system are closely interrelated. Crew members of CONCORDIA station have a prolonged stay (roughly 12 months) in a confined (antigen exposure restricted, overclean) and isolated environment, mimicking the situation of long-term space travel. ICELAND-2 will be conducted over three consecutive winter-over periods (3 years).

The project ICELAND-2:

  1. evaluates the effect of the probiotic BL1714 on well-being regarding mood, social integration and stress and other parameters .
  2. determines the effect of an antigen-limited environment like Concordia on gut microbiota, immune system and epigenetics.
  3. examines the interaction between the factors mentioned in 1.
  4. examines the role of nutrition intake and behaviour in the interplay mentioned above.
Read the detailed description

EXPERIMENT CONCEPT

This is a double-bind, controlled pilot study where volunteers will receive a novel nutritional supplement powder (sachet, containing 1011 CFU Bifidobacterium longum 1714 (Alimentary 11 Health, Cork, Ireland) or placebo) once every day, to be taken in the morning with breakfastthroughout the year. The intervention starts for every participant at arrival (individual start). Using this study design, benefits of the probiotic on height adaptation can be also studied.

The experimental concept is based on the collection of biosamples (saliva, blood, stool) and some paper-pencil and documentary data only. Thereby, the interference of the project with the daily activities of the CONCORDIA crew is minimal. Both, female and male participants are included.

  1. One blood, one saliva and one stool sample prior to the CONCORDIA stay, in addition to paper-pencil data collection once at the same time (-2 to 3 months prior to the stay - T Zero, BDC)
  2. Three blood as well as a saliva samples (month 1, months 4 and 9, corresponding to T0, T4 and T9) during the CONCORDIA stay, as well as monthly collection of stool samples (months 1 to 9, T1 to T9), plus questionnaire data (paper-pencil data and/or online).
  3. One blood, one saliva and one stool sample after the CONCORDIA stay, in addition to paper-pencil data collection once at the same time (3 to 6 months after the stay - T12)

Saliva Sampling: a standard saliva sampling kit (Oragene-DNA - OG-500, DNA Genotec, Ottawa, ON, Canada) will be used (see Figure 2).

Stool Sampling: a standard stool sampling kit (Sarstedt) will be used (see Figure 3) to retrieve 3 small samples from each stool, and stored in separated containers.

Feces Catcher: Paper-based stool collection aid (with instruction imprinted in variable language (FecesCatcher®) (Figure 4)

Blood sampling: Blood collection will be performed in two 5 ml heparinized tubes (total 10 ml for cell collection) and one dried tube of 5 ml per blood sampling. An adequate number of separation tubes and cryotubes for processing of blood will also be provided.

PROCEDURE OUTLINE

Saliva sampling: can be done at any time prior to the CONCORDIA stay, easiest during the pre-departure crew meeting. Saliva sampling will be repeated at month 4 and 9 as well as post CONCORDIA stay. Saliva samples do not need any preprocessing and can be stored at room temperature for the remaining time.

During the pre-departure meeting, a 1-hour interview related to nutritional habits (including gastrointestinal symptoms like bowel movements) should be done. Paper-pencil tests (1 hour) will be collected as well. This will include the Food Frequency Questionnaire (FFQ), the gastrointestinal symptom rating scale (GSRS) and a structured questionnaire related to previous illnesses, drug intake and medical treatments. The FFQ and the GSRS will be assessed in Concordia at the same times as the blood sampling is performed.

Stool sampling and short well-being assessment: Sampling (three aliquots, pea-size, in separate containers) can be done at the discretion of each participating CONCORDIA crew member once every month, but preferentially at approximately same day of the months each time. No coordinated sampling between crew members is needed, but the day should be noted on the sampling kits/diary. This should be supervised and documented by the ESA MD. Along with the stool sampling the participants will be asked to rate on a visual analogue scale mood, stress and social integrity. Additionally, the ESA MD will provide the information for every participant. This measure is needed as outcome for the RCT.

Food records: The ESA MD is asked to take pictures of meals/food/food condition on a regular base if possible. Most importantly, the MD should take standardized photos of the meals (of the last three days prior to the and the days of the stool sampling. The camera and storage devices have been handed out to the MD in Aosta, Italy.

Alternatively and/or in addition the cook will record his cooking activities.

T - 3 days before stool sampling:

ESA MD takes photo (with a reference 2 euro coin) of breakfast meal, lunch meal and dinner meal

T - 2 days before stool sampling:

ESA MD takes photo (with a reference 2 euro coin) of breakfast meal, lunch meal and dinner meal

T - 1 days before stool sampling:

ESA MD takes photo (with a reference 2 euro coin) of breakfast meal, lunch meal and dinner meal

Days of stool sampling:

ESA MD takes photo (with a reference 2 euro coin) of breakfast meal, lunch meal and dinner meal

Pre-processing of stool samples is not needed, samples are stored away at -50°C.

Blood sampling: Blood withdrawal for immune testing must be performed by a single phlebotomy, and can be performed at the time of programmed health checks of the CONCORDIA staff. Blood collection must be performed in two 5 ml heparinized tubes (total 10 ml for cell collection), and one dried tube of 5 ml for serum.

Pre-processing of the Blood Sample (to be performed by the ESA investigator physician)

For cognate immune functions, live cells are needed and must be frozen and stored in preserving conditions so they can be resuscitated after that. This means rapid processing after collection (within 4-6 hours), fast freezing and in preserving medium (with DMSO) below -40°C.

Blood Cell storage: Vacutainer® CPT™ Cell Preparation tubes with Sodium Heparin are provided to simplify cell preparation (Figure 5, left). CPT™ tubes directly contain ficoll (density buffer) and a gel ready for centrifugation. The blood is collected on the top of the gel like usual vacutainer tubes. Centrifugation will separate red blood cells, granulocytes (going below the gel) from mononuclear cells and plasma staying on the top. Mononuclear cells need washing in Sterile Hanks buffer (provided) and the pellet re-suspended in freezing buffer (provided) and directly frozen at least below 40°C.

Being tested
Bifidobacterium longum 1714, placebo sachet containing maltodextrin and magnesium stearate.
Keywords
probiotics, microbiota, gastrointestinal, immune system, immunology, stress, Bifidobacterium, hypoxia, confinement, isolation
Medical subject headings
Hypoxia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bifidobacterium longum 1714Dietary supplement

    This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.

  • placebo sachet containing maltodextrin and magnesium stearate.Dietary supplement

    placebo sachet containing maltodextrin and magnesium stearate.

Study groups in NCT03746145
Study groupRoleWhat they receive
Bifidobacterium longum 1714ExperimentalParticipants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
Receives: Dietary Supplement: Bifidobacterium longum 1714
PlaceboExperimentalParticipants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
Receives: Dietary Supplement: placebo sachet containing maltodextrin and magnesium stearate.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Expert rating by medical doctor on well-being of participant

    The medical doctors will rate the well-being of participants structured using 10 visual analogue scales monthly. The scales comprise the topics stress, stress coping, mood and physical health. This Rating is done ahead of the participant ratings (see sec. outcomes)

    Measured: up to 12 months

Secondary outcomes (11)
  1. Participant rating on well-being

    The participants will perform a self-rating of their well-being using the same visual analogue scales as the medical doctor for the primary outcome.

    Measured: measurement monthly over 12 months

  2. Discrepancy between ratings on well-being

    The discrepancy between the expert-rating and the self-rating will be calculated

    Measured: measurement monthly over 12 months

  3. Gastrointestinal symptoms

    Gastrointestinal symptoms will be assessed using the gastrointestinal symptom rating scale

    Measured: Measurements at 1 day predeparture, in Antarctica at months 4,9 and 12 and 6 months postdeparture

  4. Gastrointestinal microbiota

    Gastrointestinal microbiota composition and diversity measures analysed from stool samples using 16S rRNA sequencing and shotgun sequencing

    Measured: stool samples collected at 1 day predeparture, in Antarctica monthly over 1 year and 6 months postdeparture

  5. Immune system

    Cognate immune system analyzed from blood samples using FACS

    Measured: Measurements at 1 day predeparture, in Antarctica at months 4,9 and 12 and 6 months postdeparture

  6. Epigenetics

    Histone modification and DNA methylation with focus on immune biology (DNA from saliva samples) using state of the art techniques e.g. Chromatin immunoprecipitation (ChIP)-based methods and high-performance liquid chromatography (HPLC), bisulfite sequencing, and CpG island microarrays.

    Measured: Measurements at 1 day predeparture, in Antarctica at months 4,9 and 12 and 6 months postdeparture

  7. Interaction between microbiota and immune biology (including epigenetics)

    Interaction between microbiota and immune biology (including epigenetics) by using novel bioinformatic and statistic models e.g. distance based redundancy analysis

    Measured: Measurements at 1 day predeparture, in Antarctica at months 4,9 and 12 and 6 months postdeparture

  8. Nutrition

    Influence of nutrition and nutritional habits on healths using Food Frequency Questionnaires (FFQ) and standardized photographies of meals

    Measured: FFQ: Measurements at 1 day predeparture, in Antarctica at months 4,9 and 12 and 6 months postdeparture

  9. Medical and psychological data records assessed by the medical doctors of the European Space Agency

    Medical and psychological data records assessed by the medical doctors of the European Space Agency

    Measured: 1 day Predeparture, Antarctica winterover of 12 months

  10. POMS

    Profile of mood states (POMS) questionnaire

    Measured: 1 day Predeparture, Antarctica winterover of 12 months

  11. PANAS

    Positive \& negative affect schedule

    Measured: 1 day Predeparture, Antarctica winterover of 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2018
  2. Study start15 Nov 2018 (estimated)
  3. Primary completion1 Jul 2022 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
During the entire winter over (WO) period, from arrival at COCORDIA until departure (1 year), participants receive 2g nutritional supplement powder (sachet, containing 10e11 CFU Bifidobacterium longum 1714 or placebo) once every day, to be taken in the morning with breakfast throughout the year.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03746145
Sponsor's protocol ID
ICELAND-2
Acronym
ICELAND-2
Status last verified
Nov 2018
First submitted
8 Nov 2018
Last updated
19 Nov 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Bifidobacterium longum 1714 in people with Confinement and Isolation, run by University Hospital Tuebingen at 1 site in Antarctica.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Antarctica. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Isabelle Mack, Dr. (+4970712985614, isabelle.mack@uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Expert rating by medical doctor on well-being of participant (time frame: up to 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in